BG Medicine Forms Research Collaboration with M.D. Anderson Cancer Center to Discover Serum Biomarkers for Breast Cancer Treatment Response

BG Medicine, Inc.

BG Medicine Forms Research Collaboration with M.D. Anderson Cancer Center to Discover Serum Biomarkers for Breast Cancer Treatment Response

May 9, 2007

WALTHAM, Mass.--(BUSINESS WIRE)--BG Medicine announced today that it has entered into a research collaboration with The University of Texas M. D. Anderson Cancer Center aimed at improving the treatment of breast cancer. Under this agreement, BG Medicine will apply its biomarker discovery technology to the analysis of clinical samples provided by The University of Texas M. D. Anderson Cancer Center. The goal of the collaboration is to identify novel, specific and sensitive blood-based protein and metabolite biomarkers in breast cancer patients who are receiving selected treatments.

In the past decade several significant new medicines for the treatment of breast cancer have become available. However, they are not equally helpful or suitable for every patient. “In order to use these therapies more effectively, it is necessary to know which patients are likely to respond. Biomarkers give us an opportunity to identify who will benefit from certain treatments before the treatment is started or for whom the treatment is working early after initiation of therapy and before efficacy is clinically detectable”, said Pieter Muntendam MD, President and CEO of BG Medicine. “These treatment response diagnostics will enable more successful and cost-effective individualized oncology care than previously possible.”

While several gene-based diagnostic tissue biomarkers relevant to breast cancer have been identified, other relevant biological molecules, particularly proteins and endogenous metabolites detectable in blood, can provide important additional information for treatment decisions.

About BG Medicine

BG Medicine is a life sciences company focused on the discovery, development and commercialization of novel molecular diagnostics to improve patient outcomes and contain healthcare costs. The Company discovers biomarkers and develops molecular diagnostic tests that are intended to provide information to physicians that will improve patient treatment decisions. The Company’s molecular diagnostic tests are designed to predict a patient’s response to drug therapy, determine the potential toxicity of therapeutic agents to patients, identify patients who have or are likely to develop a specific disease, predict a patient’s prognosis and monitor a patient’s disease progression or drug response. BG Medicine uses its proprietary technology platform to identify new biomarkers by integrating and automating the measurement, analysis, characterization and interpretation of proteins and small non-protein biological molecules collected from bodily fluids or tissues. BG Medicine has collaborations and initiatives with major pharmaceutical companies, the U.S. Food and Drug Administration and other healthcare organizations. For additional information about BG Medicine, please visit www.bg-medicine.com

Contacts

Feinstein Kean Healthcare
Fintan R. Steele, Ph.D., 617-761-6796
Mobile: 617-816-9834
Fax: 617-577-8985
fintan.steele@fkhealth.com